Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.

The Journal of biological chemistry - 12 Feb 2010

Yuan Hongfeng, Wang Zhiqiang, Gao Chunggang, Chen Wengang, Huang Qin, Yee Jiing-Kuan, Bhatia Ravi, Chen WenYong

Abstract excerpt

Acquired resistance through genetic mutations is a common phenomenon in several cancer therapies using molecularly targeted drugs, best exemplified by the BCR-ABL inhibitor imatinib in treating chronic myelogenous leukemia (CML). Overcoming acquired resistance is a daunting therapeutic challenge,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoprecipitation

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Pyrimidines

Share to Reactive Oxygen Species

Source

Open in PubMed Open full text

Identifiers

PMID: 20007699
DOI: 10.1074/jbc.M109.039206
PMCID: PMC2836111

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20007699-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.PMID 20007699Read ↗

Semi‑random mutagenesis profile of BCR‑ABL during imatinib resistance acquirement in K562 cells.Semantic proximity Read ↗

A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.Semantic proximity Read ↗

Resistance to imatinib: mutations and beyond.Semantic proximity Read ↗

Resistance in the land of molecular cancer therapeutics.Semantic proximity Read ↗

Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.Semantic proximity Read ↗

Contribution of BCR–ABL‐independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cellsSemantic proximity Read ↗

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cellsSemantic proximity Read ↗

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.Semantic proximity Read ↗

Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.Semantic proximity Read ↗

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.Semantic proximity Read ↗

Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.Semantic proximity Read ↗

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.